Australia's most trusted
source of pharma news
Friday, 15 November 2024
Posted 13 November 2024 AM
MSD's Keytruda well and truly maintained its top ranking as the most reimbursed drug on the PBS over the third financial quarter with sales soaring by 43.5 per cent year-on-year.
The cancer blockbuster earned $50.7 million more than it did a year earlier. It also pulled in $10.7 million more than it did in the second quarter, for a 6.8 per cent quarter-on-quarter growth rate.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.